Trade measures: Lessons from the Harley-Davidson judgment by the ECJ
The European Court of Justice (ECJ) ruled that Harley-Davidson's relocation of production from the USA to Thailand was primarily aimed at circumventing additional EU tariffs on US motorcycles. The relocation was classified as "non-economic processing" under Article 33 of the Delegated Regulation to the Union Customs Code, as its main purpose was to evade trade measures. This led to the invalidation of the binding origin rulings (BOIs) issued by Belgian customs authorities, which had confirmed Thailand as the country of origin.
The ECJ ruling highlights the importance of a sound economic justification for production relocations. Companies shifting production must ensure that such decisions are based on legitimate economic considerations and not solely on circumventing trade measures. Proper documentation and transparency are crucial to ensure the legality of such relocations and minimize regulatory risks.
Furthermore, the case shows that relocations coinciding with trade measures such as protectionist tariffs or sanctions will be scrutinized more closely by authorities. Companies should carefully plan their production decisions, conduct legal analyses of relevant trade and customs regulations, and demonstrate the economic viability of the measures. The Harley-Davidson ruling underscores the need for a proactive and compliant approach to avoid regulatory uncertainties and potential economic disadvantages.
Centralized Clearance for Import (CCI): Expansion in the EU
The Centralized Clearance for Import (CCI) system, introduced in July 2024, is being gradually rolled out across the EU. After Croatia joined the system on 30 September 2024, Italy became part of it on 8 November 2024. CCI is based on the Union Customs Code and simplifies and digitalizes customs clearance across member state borders.
Currently, the system is operational in ten member states: Bulgaria, Estonia, Spain, Luxembourg, Latvia, Lithuania, Poland, Romania, Croatia, and Italy. The next phase of implementation, planned for June 2025, will include features such as simplified customs declarations, entries into the declarant's records, inclusion of consumables, and consideration of excise tax areas. By this time, all other member states are expected to join the system, making the CCI system increasingly significant for cross-border trade.
The CCI system significantly facilitates international trade. It enables faster customs clearance, reduces administrative hurdles, eliminates unnecessary transit procedures, cuts costs, and improves compliance with regulations. For businesses, this means less effort and greater competitiveness globally. Early preparation for the expansion of the CCI system is crucial for affected companies.
European Commission releases 2025 version of the Combined Nomenclature
The European Commission has published the latest version of the Combined Nomenclature (CN), which applies from 1 January 2025. The CN serves as the foundation for the declaration of goods during import, export, and intra-union trade statistics. It determines the applicable customs duties and the treatment of goods for statistical purposes. The Combined Nomenclature is an essential tool for both businesses and customs administrations of member states and is updated annually.
The new version of the CN for 2025 introduces some significant updates. New tariff codes have been added for products such as “sharks and shark fins” in Chapter 3, “tomatoes” in Chapter 7, “biofuels” in Chapter 27, “wood waste” and “laminate floor coverings” in Chapter 44, and “steel laminations and stator and rotor cores” in Chapter 85.
These changes are important for companies engaged in international trade as they directly impact product classification and related customs duties. Businesses are advised to familiarize themselves with the new nomenclature early to ensure smooth customs processing and compliance with the updated regulations.
New guidelines for the export of cyber surveillance items
The European Commission has published guidelines to better control the export of cyber surveillance items. The aim is to minimize the risks associated with the misuse of such technologies and provide exporters with practical tools for assessing human rights risks. The guidelines offer exporters a step-by-step approach to reviewing transactions and help identify risks such as internal repression or human rights violations.
If a risk is identified, exporters are required to submit an export notification to the relevant national authority. The measures are based on the Dual-Use Regulation, which governs the export of such technologies, as they can be used legally but also misused.
Pharma VAT Recovery for Rebates granted under KVV Art. 71a: A Smart Business Move for You
Pharmaceutical companies selling drugs listed on the Speciality List (SL) in Switzerland have the opportunity to gain a valuable VAT benefit that could significantly enhance their financial standing. The reason for this opportunity is a recent shift in the approach of health and/or disability insurers regarding the rebates required under Swiss law (KVV Article 71a).
Previously, pharmaceutical companies had to grant rebates for Specialty List (SL) medicines under KVV Art. 71a if those drugs had been used in special cases, the price had to be below the price listed on the SL with no further stipulation in the law.
Non-SL drugs (which typically are not reimbursed by the health insurance) are reimbursed in special cases under KVV Art 71b, the prices in those cases were subject to negotiation between the health insurance and the pharmaceutical company. Rebates in those cases were not obligatory, but often agreed upon in the negotiations.
The partial revision of the KVV which went into force on 1 January 2024 now requires pharmaceutical companies to grant a set percentage of rebate on drugs reimbursed in special cases, regardless of whether those Drugs are listed in the SL or not, the same rebates apply for both SL and non-SL drugs.
Until recently, these rebates were usually issued with VAT on the credit notes, but recently, many insurers have requested the credit notes to be issued without VAT, to avoid any VAT risk on their side.
This change implies that pharmaceutical companies may have inadvertently VAT on these rebates in the past that can be claimed back. The good news is that such overpaid VAT amounts can be reclaimed from the Swiss VAT authorities, provided that a VAT ruling confirming this option is in place. We've been instrumental in assisting numerous pharmaceutical clients in securing these rulings, enabling them to recoup substantial VAT sums spanning the past five years.
A comprehensive exploration of the KVV Art 71a to c revision from a tax perspective can be found in our recent blog post.
Our Swiss Pharma Regulatory and Indirect Tax experts are looking forward to discussing VAT refund opportunities together with you.
EU VAT package ViDA (VAT in the Digital Age) adopted
The European Council has adopted the VAT in the Digital Age (‘ViDA’) package on 5 November 2024. This means that significant changes will be made to the EU VAT system starting from 2028.
The following changes have been approved in this regard:
- Digital Reporting Requirements (DRR) and mandatory e-invoicing on intra-EU business-to-business (B2B) transactions - the application date and transitional date for DRR are 1 July 2030 and 1 January 2035 respectively;
- The platform economy - the application date is 1 July 2028 (at the earliest) with a mandatory application date of 1 January 2030; and
- Simplifying VAT compliance by taking away the need for multiple VAT registrations - application date of 1 July 2028.
Environment – Social – Government («ESG») levies
In the EU, we are currently witnessing significant developments in the ESG (Environmental, Social, Governance) tax landscape. New levies are constantly being introduced, both small and large, which require our attention. These include among other plastic packaging taxes, sugar taxes, and the extended producer responsibility. All of these topics fall within the realm of ESG and are becoming increasingly important.